EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. The Company has raised $30 million USD (£23 million GBP) in this round, which was led by new investor Foresite Capital. Existing investors, Draper Esprit, DCVC (Data Collective), the Morningside group, Providence Investment Company, Cambridge Consultants Ltd, Rising Tide Fund, and Civilization Ventures, also all participated in the round.

We help our customers turn biological innovation into business value.

Evonetix is the latest in a line of successful companies that trace their roots back to Cambridge Consultants. Cambridge Consultants has created more than 20 companies in its long history, with many that have changed market dynamics and disrupted whole industries. Several of these companies, including CSR, Domino and Xaar, have gone on to be listed on the London Stock Exchange. In all, Cambridge Consultants has created over £1 billion GBP worth of value and more than 3,000 jobs through its spinouts and is seen by many as a founding father of ‘the Cambridge Phenomenon’.

The new funding will be used to accelerate internal technology development, including the integration of Evonetix’s technology to enable the synthesis of DNA on a chip. The investment will fund the Company through to the introduction of its desktop DNA platform which, once fully developed, will facilitate and enable the rapidly growing field of synthetic biology, with application across industries including healthcare, pharma, biotech, food and agriculture and data storage. The investment will also support the Company’s significant recruitment plans, as it continues to increase headcount across scientific, operational and commercial staff located at Evonetix’s state-of-the-art facility at Coldhams Business Park, Cambridge, UK.

Evonetix was founded in 2015, to develop technology that enables the parallel synthesis of DNA on silicon arrays, to facilitate the fast-emerging field of synthetic biology, where there is increasing demand for high-throughput and highly accurate DNA synthesis. The Company was founded by Cambridge Consultants and Providence Investment Company Limited, and went on to close $12.3 million USD Series A funding in 2018, in addition to a grant from Innovate UK. The close of the Series B round brings the total funds raised by the Company to $46 million to date. The Company has the backing of the technology entrepreneur and venture capitalist Hermann Hauser.

The Company’s technology utilises a silicon chip, made by microelectromechanical systems (MEMS) processing, that controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of magnitude better than conventional approaches.

Dr Tim Brears, Evonetix CEO, said: “The backing of both our existing and new investors will enable us to fast track development, testing and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not possible with existing approaches.”

Jim Tananbaum, CEO and Managing Director at Foresite Capital, said: “Evonetix is developing a desktop, short latency solution to synthesise DNA. We are delighted to support the team in their mission to make biological engineering as accessible and widespread as next-generation sequencing.”

Vishal Gulati, Venture Partner, Draper Esprit, added: “The next set of breakthroughs in healthcare and synthetic biology will come from technologies that can go beyond reading DNA to writing it. Evonetix is leveraging the UK's strength in DNA research to build this unique, ground-breaking DNA synthesis platform. We’re excited to welcome Foresite Capital, one of the world's leading life-sciences investors, to support this Company to achieve the next stage of its growth and look forward to working closely with this talented team.”

Armen Vidian, Evonetix Board member and Partner at DCVC, said: “DCVC is pleased to continue its commitment to synthetic biology with its renewed investment in Evonetix. As demand grows to use synthetic biology for everything from sustaining agriculture to creating precision medicines and synthetic fuels, Evonetix will be well-positioned to meet those more complex needs with highly accurate, high throughput, long-strand DNA synthesis.”

Notes to editors

ケンブリッジコンサルタンツは、画期的な製品開発、知的所有権の創出や供与、技術的な難題に対するビジネスコンサルティングを、世界中のお客様に向けて行っています。市場初となる製品の立ち上げや新規市場参入、新技術導入による既存市場の拡大など、お客様がビジネスチャンスを成功へと変えるお手伝いを60年以上にわたり継続してきました。英国ケンブリッジ、米国ボストン、東京、シンガポールに、エンジニアや科学者、数学者やデザイナーを含む900名以上のスタッフを擁し、医療機器、ライフサイエンス、産業機械、エネルギー、消費財、流通、通信、インフラストラクチャなど、多様な分野におけるソリューションを提供しています。詳細はwww.cambridgeconsultants.comをご参照ください。

ケンブリッジコンサルタンツは、デジタルイノベーション、コンサルティング、トランスフォーメーションを統合したグローバル・ビジネス・ライン、「キャップジェミニ・インベント」の一員です。キャップジェミニ・インベントは、経営責任者たちの構想、次の一手の策定支援を行います。世界中の30のオフィスと25のクリエイティブ・スタジオにある7,000以上の強力なチームで構成され、戦略、技術、データサイエンス、クリエイティブ設計領域において、市場をリードする専門家集団を組織します。

キャップジェミニ・インベントは、テクノロジーの力を活用して企業ビジネスの変革・管理を支援するパートナーシップにおけるグローバルリーダーである、キャップジェミニの一部門です。キャップジェミニ・グループは、テクノロジーを通して人々が持つエネルギーを解き放つことで、包摂的で持続可能な未来を目指し、日々まい進しています。世界約50ケ国の27万人に及ぶチームメンバーから成る、極めて多様的で責任感の強い組織です。キャップジェミニは、50年にわたって積み上げてきた経験と実績そして豊かな専門知識を活かし、クラウド、データ、AI、コネクティビティ、ソフトウェア、デジタルエンジニアリング、プラットフォームなど、急速に進化するイノベーティブなテクノロジーを原動力として、戦略から設計、オペレーションに至るまで、お客様の幅広いビジネスニーズすべてに対応して、お客様から厚い信頼をいただいています。グループ全体の2020年度の売上は、160億ユーロです。

Get the Future You Want – 望む未来を手に入れよう | www.capgemini.com

About Evonetix Ltd

Evonetix is reimagining biology by developing a radically different approach to gene synthesis – a highly parallel desktop platform to synthesise DNA at unprecedented accuracy and scale. The Company’s platform will place DNA synthesis in the hands of every researcher and change how DNA is accessed, made and used. This new paradigm in gene synthesis will facilitate and enable the rapidly growing field of synthetic biology. 

The proprietary Evonetix approach utilises a silicon chip, made by MEMS processing, that integrates physics with biology, and controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. The approach is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, providing accuracy that is several orders of magnitude better than the conventional approach. 

The Evonetix DNA writer will be a desktop device, available to every researcher, and providing scalable, accurate DNA synthesis to enable biological systems to be engineered with unprecedented accuracy and scale – this is third-generation DNA synthesis. 

For further information, see www.evonetix.com 

メディア関係者連絡先

WE Communications

Matt
Urquhart